B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Furie, Richard; Aroca, Gustavo; D. Cascino, Matthew; Garg, Jay; H. Rovin, Brad; Álvarez, Analía; Fragoso-Loyo, Hilda; Zuta-Santillan, Elizabeth; H. Schindler, Thomas; Brunetta, Paul; M. Looney, Cary; Hassan, Imran; Malvar, Ana

doi:10.1136/annrheumdis-2021-220920

Public

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Published in Annals of the Rheumatic Diseases • Jan 1, 2022

Authors:

Richard Furie

Gustavo Aroca

Matthew D. Cascino

Abstract

OBJECTIVE: Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, with placebo for the treatment of LN i...

Subject

Obinutuzumab

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!